Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70118 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Yizhe Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine and Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Primary Myelofibrosis, Pyrrolidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Bristol Myers Squibb, Princeton, NJ, USA, Bristol Myers Squibb, Bristol-Myers Squibb Canada.
Abstract (Originalsprache)
Aims
Fedratinib is a potent, oral, Janus kinase inhibitor for the treatment of myelofibrosis (MF). This report describes exposure–response (E–R) analyses of fedratinib based on pooled data from phase 2/3 studies in patients with intermediate‐2 or high‐risk MF, with or without prior ruxolitinib exposure.
Methods
Pharmacokinetic (PK) exposures were derived from the population PK analysis. Efficacy endpoints included spleen volume reduction ≥35% (SVR35) and total symptom score reduction ≥50% (TSS response). Safety endpoints included grade ≥3 anaemia or thrombocytopenia, any‐grade nausea/vomiting and diarrhoea. The E–R models were developed using logistic regression analyses.
Results
Fedratinib exposure was positively associated with SVR35 (odds ratio [OR], 38.2; 95% confidence interval [CI], 12.4–118; P < 0.001) and TSS response (OR, 20.8; 95% CI, 6.27–69.2; P < 0.001), after adjusting for covariates. Baseline spleen volume was inversely associated with SVR35 ( P = 0.029). Prior ruxolitinib exposure was not associated with SVR35 ( P = 0.090) or TSS response ( P = 0.326). Although numerically higher incidence of adverse events was observed in patients with higher fedratinib exposure, there was no statistically significant association between fedratinib exposure and any safety related endpoints. Prior ruxolitinib exposure was associated with experiencing grade ≥3 thrombocytopenia ( P = 0.004). Lower baseline haemoglobin level (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Medicine and Clinical Pharmacology, Bristol Myers Squibb, Princeton, NJ, USA.
- Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.
- Worldwide Patient Safety, Bristol Myers Squibb, Princeton, NJ, USA.
ORCID-Profile: Yizhe Chen, Ken Ogasawara
Förderung
- Bristol Myers Squibb, Princeton, NJ, USA
- Bristol Myers Squibb
- Bristol-Myers Squibb Canada
Zitieren
APA
Chen, Y., Li, Y., Xue, Y., Brown, P., Hernandez, C., Rose, S., Pilot, R., Krishna, G., & Ogasawara, K. (2025). Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70118
Vancouver
Chen Y, Li Y, Xue Y, Brown P, Hernandez C, Rose S, et al. Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70118
BibTeX
@article{Chen2025,
author = {Chen, Yizhe and Li, Yan and Xue, Yongjun and Brown, Patrick and Hernandez, Christopher and Rose, Shelonitda and Pilot, Richard and Krishna, Gopal and Ogasawara, Ken},
title = {Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70118}
}
EUVIMED